Anika Therapeutics Q1 Earnings Call Highlights

Key Points

• First‑quarter revenue rose 13% year‑over‑year to $29.6 million, driven by double‑digit commercial channel growth—led by Integrity (U.S. procedures +35% Y/Y; Integrity revenue nearly $2 million) and about $9 million in international OA sales.
• Margins and profitability improved—GAAP gross margin increased to 64% from 56% and adjusted EBITDA was $4.3 million—although SG&A included $4.9 million of one‑time severance; the company reiterated 2026 guidance of $114–$122.5 million in revenue and a 5–10% adjusted EBITDA margin.
• Pipeline/regulatory milestones: the Hyalofast PMA review is ongoing after a deficiency letter with resubmission expected "in the coming months," Cingal's bioequivalence study and EU MDR certification are progressing, and an early-stage suture/tape program shows encouraging preclinical data.

Anika Therapeutics NASDAQ: ANIK reported first-quarter 2026 results highlighting continued momentum in its commercial channel, progress in its hyaluronic acid (HA)-based product pipeline, and early benefits from operational changes aimed at improving profitability and scalability.

Commercial channel growth led by Integrity and international OA portfolio

President and CEO Steve Griffin said the company made “meaningful progress” across three priorities: “driving sustainable commercial channel growth, advancing our hyaluronic acid-based innovation pipeline, and strengthening execution across our organization.”

Griffin said commercial channel revenue grew at a double-digit rate in the quarter, supported by performance in both Regenerative Solutions and the company’s international osteoarthritis (OA) pain management portfolio. In Regenerative Solutions, he pointed to Integrity as a key driver, with U.S. procedures up 35% year-over-year and “nearly $2 million in revenue.” Griffin added that Integrity has “now surpassed 3,000 cases with accelerating adoption,” and that surgeons are moving to their fifth and tenth cases faster than initially expected.

Griffin also emphasized the market opportunity for rotator cuff augmentation, noting augmentation is used in “only about 8% of rotator cuffs in the U.S.” He said the company’s strategy is to expand Integrity with “additional sizes, configurations, and enabling instrumentation” to make adoption easier for surgeons and expand the total addressable market over time.

Hyalofast contributed steady growth outside the U.S., Griffin said, citing solid international demand and continued market expansion. In international OA pain management, Griffin said first-quarter revenue was “nearly $9 million,” driven by regional expansion and market share gains for Cingal, Monovisc, and Orthovisc.

OEM channel variability and product mix dynamics

Senior Vice President, Chief Accounting Officer, and Treasurer Ian McLeod reported total first-quarter revenue of $29.6 million, up 13% year-over-year. Commercial channel revenue rose 12% to $12.6 million, while OEM channel revenue increased 14% to $17.0 million.

McLeod said the OEM increase was “driven primarily by order timing,” including shipments of U.S. OA pain management products sold through J&J MedTech and certain non-orthopedic OEM products. He cautioned that some revenue “shifted into the first quarter,” which could affect reported OEM revenue in the second quarter, but said the timing shift “does not change our expectations for the full year.”

Griffin noted that within the U.S. OA pain management portfolio, Monovisc unit volumes exceeded internal projections and more than offset lower-than-expected demand for Orthovisc, with pricing “tracking in line with expectations.” He described the quarter’s product-level mix as evidence of the variability in the OEM channel.

Margin expansion, one-time severance charges, and improved adjusted EBITDA

Anika posted a sharp improvement in gross margin, which Griffin attributed to manufacturing productivity, throughput, and operational discipline tied to the company’s lean manufacturing efforts. McLeod said GAAP gross margin increased to 64% from 56% in the prior-year quarter, driven by higher volumes and “the early benefits of our lean manufacturing efforts.”

Operating expenses totaled $24.5 million, up from $19.0 million a year ago. McLeod said SG&A rose to $17.8 million from $12.9 million, “primarily reflecting $4.9 million of one-time severance-related costs” from previously announced cost-reduction actions. R&D expense increased 11% to $6.6 million, reflecting investment in regulatory and clinical programs including Hyalofast and Cingal.

Adjusted EBITDA for the quarter was $4.3 million. Griffin said adjusted EBITDA increased by more than $4 million compared with the first quarter of last year, emphasizing the results were driven by a deliberate operational transformation rather than “a single quarter or a one-time action.”

Pipeline updates: Hyalofast PMA review, Cingal progress, and early suture/tape program

On the regulatory front, Griffin said the Hyalofast PMA review is ongoing and that the company continues to engage with the FDA. During Q&A, he said the company submitted the “third and final module in the fourth quarter of 2025,” received a deficiency letter in the first quarter of 2026, and is working on responses. He did not provide a specific resubmission date but said it is “in the coming months,” with an expectation of continued back-and-forth tied to clinical data discussions.

For Cingal, Griffin said enrollment in the bioequivalent study “remains on track” as the company prepares for an NDA submission, including CMC work to support hyaluronic acid as a drug. He added that Cingal achieved European Union MDR certification, becoming the company’s third MDR-certified product alongside Monovisc and Hyalofast. Griffin said the certification includes expanded indications across multiple joints, including the knee, hip, shoulder, and ankle.

Griffin also said enrollment continues in the post-market clinical follow-up study supporting marketing for the Integrity EU MDR submission, with enrollment expected to complete later in the year.

Separately, Griffin said Anika is advancing an early-stage regenerative suture and tape program leveraging HYAFF technology. He described the program as early and said the company is “not yet quantifying its financial impact,” though he characterized preclinical data as “very encouraging.” In Q&A, Griffin called suture tape “a very large addressable market,” while noting it may not be “entirely addressable” for Anika and that it was too early to provide more detail.

Cash position, completed repurchase plan, and 2026 guidance reiterated

McLeod said Anika ended the quarter with $41 million in cash and no debt. He noted that the company completed a $15 million 10b5-1 stock repurchase plan initiated in November 2025, and that as of April 10 the program was complete. McLeod said the company purchased $15 million of stock at an average price of $10.76.

The company maintained its previously issued full-year 2026 guidance. McLeod reiterated expectations for:

• Total revenue: $114 million to $122.5 million (1% to 9% year-over-year growth)
• Commercial channel revenue: $53 million to $58 million (10% to 20% growth)
• OEM channel revenue: $61 million to $64.5 million (flat to down approximately 5%)
• Adjusted EBITDA margin: 5% to 10% of revenue

McLeod said the OEM outlook reflects anticipated Monovisc unit volume growth, partially offset by lower pricing, and that profitability expectations factor in benefits from cost-reduction actions and continued manufacturing productivity improvements, partially offset by “modestly lower J&J MedTech pricing.”

During Q&A on margins, Griffin said first-quarter gross margin demonstrated what the company can achieve but cautioned it would “likely [be] lower over time” and “vary quarter to quarter,” adding that expectations are “implied through the EBITDA guidance” rather than a specific gross margin target.

Griffin also noted governance changes tied to the company’s post-divestiture phase, saying two directors—Dr. Glenn R. Larsen and William Jellison—will be stepping down, as outlined in the proxy filing.

About Anika Therapeutics NASDAQ: ANIK

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika's proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company's core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.